Vita Life Sciences Past Earnings Performance
Past criteria checks 4/6
Vita Life Sciences has been growing earnings at an average annual rate of 19.8%, while the Pharmaceuticals industry saw earnings growing at 35.4% annually. Revenues have been growing at an average rate of 14.1% per year. Vita Life Sciences's return on equity is 19.3%, and it has net margins of 11.9%.
Key information
19.8%
Earnings growth rate
19.7%
EPS growth rate
Pharmaceuticals Industry Growth | 31.2% |
Revenue growth rate | 14.1% |
Return on equity | 19.3% |
Net Margin | 11.9% |
Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
Recent updates
Vita Life Sciences Limited (ASX:VLS) Looks Inexpensive But Perhaps Not Attractive Enough
Sep 23Vita Life Sciences (ASX:VLS) Has Announced A Dividend Of A$0.035
Aug 28Vita Life Sciences Limited (ASX:VLS) Stock Catapults 26% Though Its Price And Business Still Lag The Market
Mar 22Vita Life Sciences (ASX:VLS) Has Announced That It Will Be Increasing Its Dividend To A$0.06
Mar 14Vita Life Sciences' (ASX:VLS) Shareholders Will Receive A Bigger Dividend Than Last Year
Feb 28A Look At The Fair Value Of Vita Life Sciences Limited (ASX:VLS)
Dec 20Should You Be Adding Vita Life Sciences (ASX:VLS) To Your Watchlist Today?
Aug 24If You Like EPS Growth Then Check Out Vita Life Sciences (ASX:VLS) Before It's Too Late
May 14Did Vita Life Sciences' (ASX:VLS) Share Price Deserve to Gain 83%?
Mar 18Vita Life Sciences Limited (ASX:VLS) On An Uptrend: Could Fundamentals Be Driving The Stock?
Feb 17Vita Life Sciences (ASX:VLS) Is Growing Earnings But Are They A Good Guide?
Jan 20Here's Why We Think Vita Life Sciences (ASX:VLS) Is Well Worth Watching
Dec 22Vita Life Sciences Limited's (ASX:VLS) Stock Has Shown Weakness Lately But Financial Prospects Look Decent: Is The Market Wrong?
Nov 19Vita Life Sciences Limited's (ASX:VLS) Prospects Need A Boost To Lift Shares
Jul 14Revenue & Expenses Breakdown
How Vita Life Sciences makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
30 Jun 24 | 79 | 9 | 34 | 0 |
31 Mar 24 | 77 | 9 | 32 | 0 |
31 Dec 23 | 74 | 9 | 31 | 0 |
30 Sep 23 | 71 | 8 | 30 | 0 |
30 Jun 23 | 69 | 7 | 29 | 0 |
31 Mar 23 | 68 | 7 | 29 | 0 |
31 Dec 22 | 67 | 7 | 29 | 0 |
30 Sep 22 | 65 | 8 | 27 | 0 |
30 Jun 22 | 64 | 8 | 26 | 0 |
31 Mar 22 | 61 | 8 | 25 | 0 |
31 Dec 21 | 57 | 8 | 24 | 0 |
30 Sep 21 | 54 | 8 | 23 | 0 |
30 Jun 21 | 50 | 7 | 22 | 0 |
31 Mar 21 | 48 | 6 | 22 | 0 |
31 Dec 20 | 46 | 6 | 21 | 0 |
30 Sep 20 | 46 | 6 | 22 | 0 |
30 Jun 20 | 45 | 5 | 22 | 0 |
31 Mar 20 | 44 | 4 | 23 | 0 |
31 Dec 19 | 42 | 3 | 23 | 0 |
30 Sep 19 | 42 | 2 | 23 | 0 |
30 Jun 19 | 41 | 2 | 23 | 0 |
31 Mar 19 | 41 | 2 | 22 | 0 |
31 Dec 18 | 41 | 2 | 21 | 0 |
30 Sep 18 | 40 | 3 | 21 | 0 |
30 Jun 18 | 40 | 4 | 21 | 0 |
31 Mar 18 | 38 | 3 | 20 | 0 |
31 Dec 17 | 37 | 3 | 20 | 0 |
30 Sep 17 | 37 | 3 | 20 | 0 |
30 Jun 17 | 37 | 3 | 20 | 0 |
31 Mar 17 | 38 | 3 | 20 | 0 |
31 Dec 16 | 38 | 3 | 20 | 0 |
30 Sep 16 | 38 | 4 | 20 | 0 |
30 Jun 16 | 38 | 5 | 20 | 0 |
31 Mar 16 | 39 | 5 | 21 | 0 |
31 Dec 15 | 39 | 4 | 21 | 0 |
30 Sep 15 | 38 | 4 | 20 | 0 |
30 Jun 15 | 37 | 4 | 20 | 0 |
31 Mar 15 | 37 | 6 | 20 | 0 |
31 Dec 14 | 37 | 7 | 19 | 0 |
30 Sep 14 | 36 | 7 | 19 | 0 |
30 Jun 14 | 36 | 7 | 19 | 0 |
31 Mar 14 | 36 | 6 | 19 | 0 |
31 Dec 13 | 35 | 5 | 18 | 0 |
Quality Earnings: VLS has high quality earnings.
Growing Profit Margin: VLS's current net profit margins (11.9%) are higher than last year (10.8%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: VLS's earnings have grown by 19.8% per year over the past 5 years.
Accelerating Growth: VLS's earnings growth over the past year (26.6%) exceeds its 5-year average (19.8% per year).
Earnings vs Industry: VLS earnings growth over the past year (26.6%) did not outperform the Pharmaceuticals industry 46.5%.
Return on Equity
High ROE: VLS's Return on Equity (19.3%) is considered low.